The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis

NCT05847751 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2026-01-07

No results posted yet for this study

Summary

The objective of this study is to evaluate the ACURATE Neo2 in the Middle East population with severe, symptomatic aortic stenosis.

Conditions

  • Severe Aortic Valve Stenosis

Interventions

DEVICE

Aortic valve replacement

Trans Aortic Valve Replacement (TAVI)

Sponsors & Collaborators

  • European Cardiovascular Research Center

    collaborator NETWORK
  • Ceric Sàrl

    lead INDUSTRY

Principal Investigators

  • Mohamed BALGHITH, MD · King Fahad National Guard Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-06
Primary Completion
2026-04-30
Completion
2026-05-31

Countries

  • Egypt
  • Lebanon
  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05847751 on ClinicalTrials.gov